|
|
|
| Exploring the Curative Efficacy and Mechanism of Thalidomide Combined with GemOx Regimen in Treating B-NHL Patients |
| LI jianan, et al |
| The Second Affiliated Hospital of Guangxi University of Science and Technology, Guangxi Liuzhou 545006, China |
|
|
|
|
Abstract Objective: To explore the efficacy and mechanism of thalidomide combined with GemOx regimen (oxaliplatin + gemcitabine) in patients with relapsed and refractory B cell non-Hodgkin's lymphoma (B-NHL). Methods: Forty patients with relapsed refractory B-NHL were randomly divided into two groups. 20 patients in the treatment group were treated with thalidomide plus GemOx regimen, and 20 patients in the control group were treated with GemOx regimen. In addition, 20 healthy subjects in the same period were selected as the normal group. The levels of TNF-α and IL-6 in peripheral blood were detected by Elisa, and TH17 and NK cell ratio in peripheral blood were detected by Flow cytometry. Results: Compared with the control group, the total effective rate of the treatment group was higher, and the incidence of thrombocytopenia, leucopenia, anemia, gastrointestinal reaction, liver and kidney dysfunction was lower (P＜0.05). The levels of TNF-α, IL-6, TH17 and NK cells were significantly higher in treatment group and control group than those in control group (P＜0.05). Compared with before treatment, the levels of TNF-α and IL-6 in treatment group and control group were significantly lower, the ratio of Th17 cells was higher (P＜0.05) , the ratio of NK cells was lower in control group, and the ratio of NK cells was higher in treatment group (P＜0.05). Compared with the control group, the levels of TNF-α, IL-6, Th17 and NK cells in the treatment group were lower than those in the control group (P<0.05). Before treatment, there was no difference in TNF-α, IL-6, Th17 and NK cell ratio between treatment group and control group (P>0.05). Conclusion: Thalidomide combined with GemOx regimen is expected to improve the efficacy of treatment in B-NHL patients, decrease serum levels of TNF-α and IL-6, and increase Th17 and NK cell ratio.
|
|
|
|
|
|
[1] 苏小琴,徐爱兵,王建红,等.沙利度胺联合吉西他滨及奥沙利铂方案治疗中晚期肝癌的临床对照研究[J].胃肠病学和肝病学杂志,2012,21(7):604-606.
[2] 许卫巍.吉西他滨联合奥沙利铂治疗复发耐药老年淋巴瘤患者的疗效观察[J].中国现代药物应用,2020,14(20):143-145.
[3] 李俊,毛蕾,周雪婷,等.沙利度胺的药理学机制及其在炎症性肠病中的研究现状[J].中国临床药理学杂志,2018,34(3):387-389.
[4] 徐金发,潘明,陈倩,等.沙利度胺联合吉西他滨、奥沙利铂方案治疗晚期肝内胆管细胞癌的近期疗效观察[J].肿瘤基础与临床,2010,23(5):386-388.
[5] 谭晶,卢永刚,梁颖,等.吉西他滨联合奥沙利铂与吉西他滨单独化疗治疗晚期胰腺癌的近期疗效比较[J].昆明医学院学报,2007,28(6):83-85.
[6] 朱雄增,李小秋.解读2008年恶性淋巴瘤WHO分类-B细胞淋巴瘤[J].临床与实验病理学杂志,2010,26(2):125-130.
[7] Cheson B D,Pfistner B,Juweid M E,et al.Revised response criteria for malignant lymphoma[J].Clin Oncol,2007,25(5):579-586.
[8] Sampol A,Rodriguez J,Galmes B,et al.Gemcitabine and oxaliplatinum:an effective regimen in a patient with progressive refractory mantle cell lymphoma[J].Leuk Lymphoma,2004,45(6):1289-1291.
[9] 郑海涛,李瑞芹,郑暹雄,等.沙利度胺治疗套细胞淋巴瘤的临床疗效及不良反应研究[J].中国现代药物应用,2019,13(2):127-128.
[10] Hus I,Bojarska-Junak A,Kaminska M,et al.Imbalance in circulatory iNKT,Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma[J].Oncol Lett,2017,14(6):7957-7964. |
|
|
|
2023, Vol. 29 
